Abstract
We report a case of a large gastrointestinal stromal tumor (GIST), greater than 5 cm in diameter, in the stomach. Microscopically, high levels of mitosis were observed, indicative of a high-grade malignancy. We analyzed the c-kit gene mutations by a replication competent retrovirus assay and DNA sequencing, which revealed a c-kit mutation in exon 11. Liver metastases were detected 7 months after surgery. Patients with an exon 11 mutation of the c-kit gene are reported to have a high response to STI571 (imatinib mesylate, Glivec). Accordingly, a 1-month course of STI571 treatment clearly changed the characterization of the metastatic tumors radiographically. Thus, it may be important to analyze c-kit gene mutations in patients presenting with GISTs to predict the effectiveness of STI571 in suppressing GISTs, especially tumors thought to have malignant potential.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S Hirota K Isozaki M Yasuhiro K Hashimoto T Nishida S Ishiguro et al. (1998) ArticleTitleGain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577–80 Occurrence Handle9438854 Occurrence Handle1:CAS:528:DyaK1cXotVyhsw%3D%3D Occurrence Handle10.1126/science.279.5350.577
GD Demetri M von Mehren CD Blanke AD Van den Abbeele P Eisenberg PJ Roberts et al. (2002) ArticleTitleEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472–80 Occurrence Handle12181401 Occurrence Handle1:CAS:528:DC%2BD38XmtV2nt7s%3D Occurrence Handle10.1056/NEJMoa020461
CA Moskaluk Q Tian CR Marshall CA Rumpel DW Franquemont HF Frierson SuffixJr (1999) ArticleTitleMutations of c-kit JM domain are found in minority of human gastrointestinal stromal tumors Oncogene 18 1897–902 Occurrence Handle10086344 Occurrence Handle1:CAS:528:DyaK1MXit1ertbw%3D Occurrence Handle10.1038/sj.onc.1202496
RP Dematteo MC Heinrich WM El-Rifai G Demetri (2002) ArticleTitleClinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466–77 Occurrence Handle12094371 Occurrence Handle1:CAS:528:DC%2BD38XlslCls7o%3D Occurrence Handle10.1053/hupa.2002.124122
H Joensuu PJ Roberts M Sarlomo-Rikala LC Andersson P Tervahartiala D Tuveson et al. (2001) ArticleTitleEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052–6 Occurrence Handle11287975 Occurrence Handle1:STN:280:DC%2BD3M3gvVekuw%3D%3D Occurrence Handle10.1056/NEJM200104053441404
BL Eisenberg (2003) ArticleTitleImatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors Oncology (Huntingt) 17 1615–26
BJ Longley MJ Reguera Y Ma (2001) ArticleTitleClasses of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy Leukemia Res 25 571–6 Occurrence Handle1:CAS:528:DC%2BD3MXjslSisbg%3D Occurrence Handle10.1016/S0145-2126(01)00028-5
GD Demetri (2001) ArticleTitleTargeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options Semin Oncol 28 19–26 Occurrence Handle11740803 Occurrence Handle1:STN:280:DC%2BD3MnptlOgtg%3D%3D Occurrence Handle10.1016/S0093-7754(01)90099-5
DM Ross TP Hughes (2004) ArticleTitleCancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer 90 12–9 Occurrence Handle14710199 Occurrence Handle1:CAS:528:DC%2BD2cXhtFKmsQ%3D%3D Occurrence Handle10.1038/sj.bjc.6601507
CL Scaife KK Hunt SR Patel RS Benjamin MA Burgess LL Chen et al. (2003) ArticleTitleIs there a role for surgery in patients with unresectable cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 186 665–9 Occurrence Handle14672776 Occurrence Handle10.1016/j.amjsurg.2003.08.023
MC Heinrich CL Corles C Blanke GD Demetri H Joensuu M von Mehren et al. (2002) ArticleTitleKIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors(GISTs) Proc Am Soc Clin Oncol 21 2a
J Verweji I Judson A van Oosterom (2001) ArticleTitleSTI571: a magic bullet? Eur J Cancer 37 1816–9 Occurrence Handle10.1016/S0959-8049(01)00237-4
P Pauwels M Debiec-Rychter M Stul I De Wever AT Van Oosterom R Sciot (2005) ArticleTitleChanging phenotype of gastrointestinal stromal tumors under imatinib mesylate treatment: a potential diagnostic pitfall Histopathology 47 41–7 Occurrence Handle15982322 Occurrence Handle1:STN:280:DC%2BD2Mzjt1ShtQ%3D%3D Occurrence Handle10.1111/j.1365-2559.2005.02179.x
S Singer BP Rubin ML Lux CJ Chen GD Demetri CD Fletcher et al. (2002) ArticleTitlePrognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors J Clin Oncol 20 3898–905 Occurrence Handle12228211 Occurrence Handle1:CAS:528:DC%2BD38XntVynsLo%3D Occurrence Handle10.1200/JCO.2002.03.095
CD Fletcher JJ Berman C Corless F Gorstein J Lasota BH Longley et al. (2002) ArticleTitleDiagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459–65 Occurrence Handle12094370 Occurrence Handle10.1053/hupa.2002.123545
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsuneoka, N., Kuroki, T., Haraguchi, M. et al. Predicting the Antitumor Effects of STI571 by Analysis of c-kit Gene Mutations in Gastrointestinal Stromal Tumors of the Stomach: Report of a Case. Surg Today 36, 989–993 (2006). https://doi.org/10.1007/s00595-006-3288-4
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00595-006-3288-4